Global Transthyretin Amyloidosis (ATTR) Market 2022 by Company, Regions, Type and Application, Forecast to 2028

  • receipt Report ID : 282518
  • calendar_today Published On: Mar, 2022
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Transthyretin Amyloidosis (ATTR) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global Transthyretin Amyloidosis (ATTR) market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospitals accounting for % of the Transthyretin Amyloidosis (ATTR) global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Hereditary ATTR (HATTR) segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Transthyretin Amyloidosis (ATTR) include Pfizer, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Corino Therapeutics, and Proclara Bioscience, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Transthyretin Amyloidosis (ATTR) market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Hereditary ATTR (HATTR)

Wild-Type (WT) ATTR

Market segment by Application, can be divided into

Hospitals

Ambulatory Surgical Centers

Diagnostic Centers

Market segment by players, this report covers

Pfizer

Alnylam Pharmaceuticals

Ionis Pharmaceuticals

Corino Therapeutics

Proclara Bioscience

Arcturus Therapeutics

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Transthyretin Amyloidosis (ATTR) product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Transthyretin Amyloidosis (ATTR), with revenue, gross margin and global market share of Transthyretin Amyloidosis (ATTR) from 2019 to 2022.

Chapter 3, the Transthyretin Amyloidosis (ATTR) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Transthyretin Amyloidosis (ATTR) market forecast, by regions, type and application, with revenue, from 2023 to 2028.

Chapter 11 and 12, to describe Transthyretin Amyloidosis (ATTR) research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1 Market Overview

1.1 Product Overview and Scope of Transthyretin Amyloidosis (ATTR)

1.2 Classification of Transthyretin Amyloidosis (ATTR) by Type

1.2.1 Overview: Global Transthyretin Amyloidosis (ATTR) Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Transthyretin Amyloidosis (ATTR) Revenue Market Share by Type in 2021

1.2.3 Hereditary ATTR (HATTR)

1.2.4 Wild-Type (WT) ATTR

1.3 Global Transthyretin Amyloidosis (ATTR) Market by Application

1.3.1 Overview: Global Transthyretin Amyloidosis (ATTR) Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Hospitals

1.3.3 Ambulatory Surgical Centers

1.3.4 Diagnostic Centers

1.4 Global Transthyretin Amyloidosis (ATTR) Market Size & Forecast

1.5 Global Transthyretin Amyloidosis (ATTR) Market Size and Forecast by Region

1.5.1 Global Transthyretin Amyloidosis (ATTR) Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Transthyretin Amyloidosis (ATTR) Market Size by Region, (2017-2022)

1.5.3 North America Transthyretin Amyloidosis (ATTR) Market Size and Prospect (2017-2028)

1.5.4 Europe Transthyretin Amyloidosis (ATTR) Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size and Prospect (2017-2028)

1.5.6 South America Transthyretin Amyloidosis (ATTR) Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Transthyretin Amyloidosis (ATTR) Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Transthyretin Amyloidosis (ATTR) Market Drivers

1.6.2 Transthyretin Amyloidosis (ATTR) Market Restraints

1.6.3 Transthyretin Amyloidosis (ATTR) Trends Analysis

2 Company Profiles

2 Company Profiles

2.1 Pfizer

2.1.1 Pfizer Details

2.1.2 Pfizer Major Business

2.1.3 Pfizer Transthyretin Amyloidosis (ATTR) Product and Solutions

2.1.4 Pfizer Transthyretin Amyloidosis (ATTR) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Pfizer Recent Developments and Future Plans

2.2 Alnylam Pharmaceuticals

2.2.1 Alnylam Pharmaceuticals Details

2.2.2 Alnylam Pharmaceuticals Major Business

2.2.3 Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Product and Solutions

2.2.4 Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Alnylam Pharmaceuticals Recent Developments and Future Plans

2.3 Ionis Pharmaceuticals

2.3.1 Ionis Pharmaceuticals Details

2.3.2 Ionis Pharmaceuticals Major Business

2.3.3 Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Product and Solutions

2.3.4 Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Ionis Pharmaceuticals Recent Developments and Future Plans

2.4 Corino Therapeutics

2.4.1 Corino Therapeutics Details

2.4.2 Corino Therapeutics Major Business

2.4.3 Corino Therapeutics Transthyretin Amyloidosis (ATTR) Product and Solutions

2.4.4 Corino Therapeutics Transthyretin Amyloidosis (ATTR) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Corino Therapeutics Recent Developments and Future Plans

2.5 Proclara Bioscience

2.5.1 Proclara Bioscience Details

2.5.2 Proclara Bioscience Major Business

2.5.3 Proclara Bioscience Transthyretin Amyloidosis (ATTR) Product and Solutions

2.5.4 Proclara Bioscience Transthyretin Amyloidosis (ATTR) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Proclara Bioscience Recent Developments and Future Plans

2.6 Arcturus Therapeutics

2.6.1 Arcturus Therapeutics Details

2.6.2 Arcturus Therapeutics Major Business

2.6.3 Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Product and Solutions

2.6.4 Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 Arcturus Therapeutics Recent Developments and Future Plans

3 Market Competition, by Players

3 Market Competition, by Players

3.1 Global Transthyretin Amyloidosis (ATTR) Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Transthyretin Amyloidosis (ATTR) Players Market Share in 2021

3.2.2 Top 10 Transthyretin Amyloidosis (ATTR) Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Transthyretin Amyloidosis (ATTR) Players Head Office, Products and Services Provided

3.4 Transthyretin Amyloidosis (ATTR) Mergers & Acquisitions

3.5 Transthyretin Amyloidosis (ATTR) New Entrants and Expansion Plans

4 Market Size Segment by Type

4 Market Size Segment by Type

4.1 Global Transthyretin Amyloidosis (ATTR) Revenue and Market Share by Type (2017-2022)

4.2 Global Transthyretin Amyloidosis (ATTR) Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5 Market Size Segment by Application

5.1 Global Transthyretin Amyloidosis (ATTR) Revenue Market Share by Application (2017-2022)

5.2 Global Transthyretin Amyloidosis (ATTR) Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6 North America by Country, by Type, and by Application

6.1 North America Transthyretin Amyloidosis (ATTR) Revenue by Type (2017-2028)

6.2 North America Transthyretin Amyloidosis (ATTR) Revenue by Application (2017-2028)

6.3 North America Transthyretin Amyloidosis (ATTR) Market Size by Country

6.3.1 North America Transthyretin Amyloidosis (ATTR) Revenue by Country (2017-2028)

6.3.2 United States Transthyretin Amyloidosis (ATTR) Market Size and Forecast (2017-2028)

6.3.3 Canada Transthyretin Amyloidosis (ATTR) Market Size and Forecast (2017-2028)

6.3.4 Mexico Transthyretin Amyloidosis (ATTR) Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7 Europe by Country, by Type, and by Application

7.1 Europe Transthyretin Amyloidosis (ATTR) Revenue by Type (2017-2028)

7.2 Europe Transthyretin Amyloidosis (ATTR) Revenue by Application (2017-2028)

7.3 Europe Transthyretin Amyloidosis (ATTR) Market Size by Country

7.3.1 Europe Transthyretin Amyloidosis (ATTR) Revenue by Country (2017-2028)

7.3.2 Germany Transthyretin Amyloidosis (ATTR) Market Size and Forecast (2017-2028)

7.3.3 France Transthyretin Amyloidosis (ATTR) Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Transthyretin Amyloidosis (ATTR) Market Size and Forecast (2017-2028)

7.3.5 Russia Transthyretin Amyloidosis (ATTR) Market Size and Forecast (2017-2028)

7.3.6 Italy Transthyretin Amyloidosis (ATTR) Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Transthyretin Amyloidosis (ATTR) Revenue by Type (2017-2028)

8.2 Asia-Pacific Transthyretin Amyloidosis (ATTR) Revenue by Application (2017-2028)

8.3 Asia-Pacific Transthyretin Amyloidosis (ATTR) Market Size by Region

8.3.1 Asia-Pacific Transthyretin Amyloidosis (ATTR) Revenue by Region (2017-2028)

8.3.2 China Transthyretin Amyloidosis (ATTR) Market Size and Forecast (2017-2028)

8.3.3 Japan Transthyretin Amyloidosis (ATTR) Market Size and Forecast (2017-2028)

8.3.4 South Korea Transthyretin Amyloidosis (ATTR) Market Size and Forecast (2017-2028)

8.3.5 India Transthyretin Amyloidosis (ATTR) Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Transthyretin Amyloidosis (ATTR) Market Size and Forecast (2017-2028)

8.3.7 Australia Transthyretin Amyloidosis (ATTR) Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9 South America by Country, by Type, and by Application

9.1 South America Transthyretin Amyloidosis (ATTR) Revenue by Type (2017-2028)

9.2 South America Transthyretin Amyloidosis (ATTR) Revenue by Application (2017-2028)

9.3 South America Transthyretin Amyloidosis (ATTR) Market Size by Country

9.3.1 South America Transthyretin Amyloidosis (ATTR) Revenue by Country (2017-2028)

9.3.2 Brazil Transthyretin Amyloidosis (ATTR) Market Size and Forecast (2017-2028)

9.3.3 Argentina Transthyretin Amyloidosis (ATTR) Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Transthyretin Amyloidosis (ATTR) Revenue by Type (2017-2028)

10.2 Middle East & Africa Transthyretin Amyloidosis (ATTR) Revenue by Application (2017-2028)

10.3 Middle East & Africa Transthyretin Amyloidosis (ATTR) Market Size by Country

10.3.1 Middle East & Africa Transthyretin Amyloidosis (ATTR) Revenue by Country (2017-2028)

10.3.2 Turkey Transthyretin Amyloidosis (ATTR) Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Transthyretin Amyloidosis (ATTR) Market Size and Forecast (2017-2028)

10.3.4 UAE Transthyretin Amyloidosis (ATTR) Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

11 Research Findings and Conclusion

12 Appendix

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Transthyretin Amyloidosis (ATTR) Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Transthyretin Amyloidosis (ATTR) Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Transthyretin Amyloidosis (ATTR) Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Transthyretin Amyloidosis (ATTR) Revenue (USD Million) by Region (2017-2022)

Table 5. Global Transthyretin Amyloidosis (ATTR) Revenue Market Share by Region (2023-2028)

Table 6. Pfizer Corporate Information, Head Office, and Major Competitors

Table 7. Pfizer Major Business

Table 8. Pfizer Transthyretin Amyloidosis (ATTR) Product and Solutions

Table 9. Pfizer Transthyretin Amyloidosis (ATTR) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Alnylam Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 11. Alnylam Pharmaceuticals Major Business

Table 12. Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Product and Solutions

Table 13. Alnylam Pharmaceuticals Transthyretin Amyloidosis (ATTR) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Ionis Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 15. Ionis Pharmaceuticals Major Business

Table 16. Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Product and Solutions

Table 17. Ionis Pharmaceuticals Transthyretin Amyloidosis (ATTR) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Corino Therapeutics Corporate Information, Head Office, and Major Competitors

Table 19. Corino Therapeutics Major Business

Table 20. Corino Therapeutics Transthyretin Amyloidosis (ATTR) Product and Solutions

Table 21. Corino Therapeutics Transthyretin Amyloidosis (ATTR) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Proclara Bioscience Corporate Information, Head Office, and Major Competitors

Table 23. Proclara Bioscience Major Business

Table 24. Proclara Bioscience Transthyretin Amyloidosis (ATTR) Product and Solutions

Table 25. Proclara Bioscience Transthyretin Amyloidosis (ATTR) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. Arcturus Therapeutics Corporate Information, Head Office, and Major Competitors

Table 27. Arcturus Therapeutics Major Business

Table 28. Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Product and Solutions

Table 29. Arcturus Therapeutics Transthyretin Amyloidosis (ATTR) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. Global Transthyretin Amyloidosis (ATTR) Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 31. Global Transthyretin Amyloidosis (ATTR) Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 32. Breakdown of Transthyretin Amyloidosis (ATTR) by Company Type (Tier 1, Tier 2 and Tier 3)

Table 33. Transthyretin Amyloidosis (ATTR) Players Head Office, Products and Services Provided

Table 34. Transthyretin Amyloidosis (ATTR) Mergers & Acquisitions in the Past Five Years

Table 35. Transthyretin Amyloidosis (ATTR) New Entrants and Expansion Plans

Table 36. Global Transthyretin Amyloidosis (ATTR) Revenue (USD Million) by Type (2017-2022)

Table 37. Global Transthyretin Amyloidosis (ATTR) Revenue Share by Type (2017-2022)

Table 38. Global Transthyretin Amyloidosis (ATTR) Revenue Forecast by Type (2023-2028)

Table 39. Global Transthyretin Amyloidosis (ATTR) Revenue by Application (2017-2022)

Table 40. Global Transthyretin Amyloidosis (ATTR) Revenue Forecast by Application (2023-2028)

Table 41. North America Transthyretin Amyloidosis (ATTR) Revenue by Type (2017-2022) & (USD Million)

Table 42. North America Transthyretin Amyloidosis (ATTR) Revenue by Type (2023-2028) & (USD Million)

Table 43. North America Transthyretin Amyloidosis (ATTR) Revenue by Application (2017-2022) & (USD Million)

Table 44. North America Transthyretin Amyloidosis (ATTR) Revenue by Application (2023-2028) & (USD Million)

Table 45. North America Transthyretin Amyloidosis (ATTR) Revenue by Country (2017-2022) & (USD Million)

Table 46. North America Transthyretin Amyloidosis (ATTR) Revenue by Country (2023-2028) & (USD Million)

Table 47. Europe Transthyretin Amyloidosis (ATTR) Revenue by Type (2017-2022) & (USD Million)

Table 48. Europe Transthyretin Amyloidosis (ATTR) Revenue by Type (2023-2028) & (USD Million)

Table 49. Europe Transthyretin Amyloidosis (ATTR) Revenue by Application (2017-2022) & (USD Million)

Table 50. Europe Transthyretin Amyloidosis (ATTR) Revenue by Application (2023-2028) & (USD Million)

Table 51. Europe Transthyretin Amyloidosis (ATTR) Revenue by Country (2017-2022) & (USD Million)

Table 52. Europe Transthyretin Amyloidosis (ATTR) Revenue by Country (2023-2028) & (USD Million)

Table 53. Asia-Pacific Transthyretin Amyloidosis (ATTR) Revenue by Type (2017-2022) & (USD Million)

Table 54. Asia-Pacific Transthyretin Amyloidosis (ATTR) Revenue by Type (2023-2028) & (USD Million)

Table 55. Asia-Pacific Transthyretin Amyloidosis (ATTR) Revenue by Application (2017-2022) & (USD Million)

Table 56. Asia-Pacific Transthyretin Amyloidosis (ATTR) Revenue by Application (2023-2028) & (USD Million)

Table 57. Asia-Pacific Transthyretin Amyloidosis (ATTR) Revenue by Region (2017-2022) & (USD Million)

Table 58. Asia-Pacific Transthyretin Amyloidosis (ATTR) Revenue by Region (2023-2028) & (USD Million)

Table 59. South America Transthyretin Amyloidosis (ATTR) Revenue by Type (2017-2022) & (USD Million)

Table 60. South America Transthyretin Amyloidosis (ATTR) Revenue by Type (2023-2028) & (USD Million)

Table 61. South America Transthyretin Amyloidosis (ATTR) Revenue by Application (2017-2022) & (USD Million)

Table 62. South America Transthyretin Amyloidosis (ATTR) Revenue by Application (2023-2028) & (USD Million)

Table 63. South America Transthyretin Amyloidosis (ATTR) Revenue by Country (2017-2022) & (USD Million)

Table 64. South America Transthyretin Amyloidosis (ATTR) Revenue by Country (2023-2028) & (USD Million)

Table 65. Middle East & Africa Transthyretin Amyloidosis (ATTR) Revenue by Type (2017-2022) & (USD Million)

Table 66. Middle East & Africa Transthyretin Amyloidosis (ATTR) Revenue by Type (2023-2028) & (USD Million)

Table 67. Middle East & Africa Transthyretin Amyloidosis (ATTR) Revenue by Application (2017-2022) & (USD Million)

Table 68. Middle East & Africa Transthyretin Amyloidosis (ATTR) Revenue by Application (2023-2028) & (USD Million)

Table 69. Middle East & Africa Transthyretin Amyloidosis (ATTR) Revenue by Country (2017-2022) & (USD Million)

Table 70. Middle East & Africa Transthyretin Amyloidosis (ATTR) Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Transthyretin Amyloidosis (ATTR) Picture

Figure 2. Global Transthyretin Amyloidosis (ATTR) Revenue Market Share by Type in 2021

Figure 3. Hereditary ATTR (HATTR)

Figure 4. Wild-Type (WT) ATTR

Figure 5. Transthyretin Amyloidosis (ATTR) Revenue Market Share by Application in 2021

Figure 6. Hospitals Picture

Figure 7. Ambulatory Surgical Centers Picture

Figure 8. Diagnostic Centers Picture

Figure 9. Global Transthyretin Amyloidosis (ATTR) Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 10. Global Transthyretin Amyloidosis (ATTR) Revenue and Forecast (2017-2028) & (USD Million)

Figure 11. Global Transthyretin Amyloidosis (ATTR) Revenue Market Share by Region (2017-2028)

Figure 12. Global Transthyretin Amyloidosis (ATTR) Revenue Market Share by Region in 2021

Figure 13. North America Transthyretin Amyloidosis (ATTR) Revenue (USD Million) and Growth Rate (2017-2028)

Figure 14. Europe Transthyretin Amyloidosis (ATTR) Revenue (USD Million) and Growth Rate (2017-2028)

Figure 15. Asia-Pacific Transthyretin Amyloidosis (ATTR) Revenue (USD Million) and Growth Rate (2017-2028)

Figure 16. South America Transthyretin Amyloidosis (ATTR) Revenue (USD Million) and Growth Rate (2017-2028)

Figure 17. Middle East and Africa Transthyretin Amyloidosis (ATTR) Revenue (USD Million) and Growth Rate (2017-2028)

Figure 18. Transthyretin Amyloidosis (ATTR) Market Drivers

Figure 19. Transthyretin Amyloidosis (ATTR) Market Restraints

Figure 20. Transthyretin Amyloidosis (ATTR) Market Trends

Figure 21. Pfizer Recent Developments and Future Plans

Figure 22. Alnylam Pharmaceuticals Recent Developments and Future Plans

Figure 23. Ionis Pharmaceuticals Recent Developments and Future Plans

Figure 24. Corino Therapeutics Recent Developments and Future Plans

Figure 25. Proclara Bioscience Recent Developments and Future Plans

Figure 26. Arcturus Therapeutics Recent Developments and Future Plans

Figure 27. Global Transthyretin Amyloidosis (ATTR) Revenue Share by Players in 2021

Figure 28. Transthyretin Amyloidosis (ATTR) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 29. Global Top 3 Players Transthyretin Amyloidosis (ATTR) Revenue Market Share in 2021

Figure 30. Global Top 10 Players Transthyretin Amyloidosis (ATTR) Revenue Market Share in 2021

Figure 31. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 32. Global Transthyretin Amyloidosis (ATTR) Revenue Share by Type in 2021

Figure 33. Global Transthyretin Amyloidosis (ATTR) Market Share Forecast by Type (2023-2028)

Figure 34. Global Transthyretin Amyloidosis (ATTR) Revenue Share by Application in 2021

Figure 35. Global Transthyretin Amyloidosis (ATTR) Market Share Forecast by Application (2023-2028)

Figure 36. North America Transthyretin Amyloidosis (ATTR) Sales Market Share by Type (2017-2028)

Figure 37. North America Transthyretin Amyloidosis (ATTR) Sales Market Share by Application (2017-2028)

Figure 38. North America Transthyretin Amyloidosis (ATTR) Revenue Market Share by Country (2017-2028)

Figure 39. United States Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 40. Canada Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 41. Mexico Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 42. Europe Transthyretin Amyloidosis (ATTR) Sales Market Share by Type (2017-2028)

Figure 43. Europe Transthyretin Amyloidosis (ATTR) Sales Market Share by Application (2017-2028)

Figure 44. Europe Transthyretin Amyloidosis (ATTR) Revenue Market Share by Country (2017-2028)

Figure 45. Germany Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 46. France Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 47. United Kingdom Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 48. Russia Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 49. Italy Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 50. Asia-Pacific Transthyretin Amyloidosis (ATTR) Sales Market Share by Type (2017-2028)

Figure 51. Asia-Pacific Transthyretin Amyloidosis (ATTR) Sales Market Share by Application (2017-2028)

Figure 52. Asia-Pacific Transthyretin Amyloidosis (ATTR) Revenue Market Share by Region (2017-2028)

Figure 53. China Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 54. Japan Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 55. South Korea Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 56. India Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 57. Southeast Asia Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 58. Australia Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. South America Transthyretin Amyloidosis (ATTR) Sales Market Share by Type (2017-2028)

Figure 60. South America Transthyretin Amyloidosis (ATTR) Sales Market Share by Application (2017-2028)

Figure 61. South America Transthyretin Amyloidosis (ATTR) Revenue Market Share by Country (2017-2028)

Figure 62. Brazil Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 63. Argentina Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 64. Middle East and Africa Transthyretin Amyloidosis (ATTR) Sales Market Share by Type (2017-2028)

Figure 65. Middle East and Africa Transthyretin Amyloidosis (ATTR) Sales Market Share by Application (2017-2028)

Figure 66. Middle East and Africa Transthyretin Amyloidosis (ATTR) Revenue Market Share by Country (2017-2028)

Figure 67. Turkey Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 68. Saudi Arabia Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. UAE Transthyretin Amyloidosis (ATTR) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 70. Methodology

Figure 71. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz